Glepaglutide - Zealand Pharma
Alternative Names: ZP 1848Latest Information Update: 22 May 2024
At a glance
- Originator Zealand Pharma
- Class Anti-inflammatories; Glucagon-like peptides
- Mechanism of Action Glucagon-like peptide 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Short bowel syndrome
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 16 May 2024 The US FDA assigns PDUFA action date of 22/12/2023 for glepaglutide for Short bowel syndrome
- 22 Dec 2023 Preregistration for Short bowel syndrome (In the elderly, In adults) in USA (SC)
- 14 Oct 2023 Efficacy data from a phase III EASE-SBS 1 trial in Short bowel syndrome presented at the 31st United European Gastroenterology Week (UEGW-2023)